Administration with TPPU, a potent sEH inhibitor-activated AKT pathway, promoted angiogenesis and restored blood supply, which finally inhibited ventricular enlargement and improved cardiac function after MI (Guo et al., 2018). The gene discussed is EPHX2; the disease is myocardial infarction.